A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
Takabayashi T, Asaka D, Okamoto Y, Himi T, Haruna S, Yoshida N, Kondo K, Yoshikawa M, Sakuma Y, Shibata K, Suzuki M, Kobayashi M, Kawata R, Tsuzuki K, Okano M, Higaki T, Takeno S, Kodama S, Yonekura S, Saito H, Nozaki A, Otori N, Fujieda S.
Takabayashi T, et al. Among authors: tsuzuki k.
Am J Rhinol Allergy. 2021 Nov;35(6):861-870. doi: 10.1177/19458924211009429. Epub 2021 Apr 11.
Am J Rhinol Allergy. 2021.
PMID: 33840229
Clinical Trial.